BLLN
BillionToOne, Inc.
$71.41
+2.00%
2026-02-26
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
Key Fundamentals
P/E Ratio
129.63
Forward P/E
70.17
EPS (TTM)
$0.72
ROE
10.7%
Revenue Growth (YoY)
64.4%
Profit Margin
8.3%
Debt/Equity
26.81
Price/Book
8.14
Market Cap
$4.40B
Avg Volume (10D)
1.1M
Recent Breakout Signals
No recent breakout signals detected for BLLN.
Recent Price Range (60 Days)
60D High
$130.00
60D Low
$66.00
Avg Volume
227K
Latest Close
$71.41
Get breakout alerts for BLLN
Sign up for Breakout Scanner to receive daily notifications when BLLN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
BillionToOne, Inc. (BLLN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BLLN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BLLN operates in the Healthcare sector within the Diagnostics & Research industry. Data is provided for informational purposes only and does not constitute financial advice.